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The elimination of autoreactive T cells from the central nervous system (CNS) by apoptosis plays an important role in switching off
autoimmune attack. B-cell apoptosis in the CNS probably also has a key role in downregulating autoimmunity. Augmenting lymphocyte apoptosis
in the CNS is a potential strategy for treating autoimmune CNS diseases such as multiple sclerosis. These strategies involve modulation of the
physiological pro-apoptotic and anti-apoptotic pathways that control lymphocyte fate in the CNS. In the case of T cells, apoptosis can be
augmented by enhancing activation-induced T-cell apoptosis through the CD95 (Fas) pathway and by inhibiting costimulation-induced anti-
apoptotic pathways mediated through BCL-2 and BCL-XL.
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Normal individuals have T lymphocytes capable of reacting
to central nervous system (CNS) antigens such as myelin basic
protein (MBP) (Martin et al., 1990). Given the high level of
cross-reactivity of T cells (Mason, 1998), it is likely that these
autoreactive T cells are often primed by exposure to cross-
reacting environmental antigens. Indeed it has been shown that
viral and bacterial peptides can activate myelin-reactive human
T cells (Wucherpfennig and Strominger, 1995; Hemmer et al.,
1997). Furthermore, normal healthy subjects experience surges
of increased frequencies of circulating myelin-reactive T cells
that might be driven by cross-reactive environmental antigens
(Pender et al., 2000). Such activated myelin-reactive T cells
would be expected to enter the CNS in healthy individuals,
because activated T cells of any specificity, including
autoreactive T cells, enter the normal CNS parenchyma
(Wekerle et al., 1986; Hickey et al., 1991). If CNS-reactive T
cells survive in the CNS, they have the potential to attack the
CNS, either directly or through the recruitment of other
inflammatory cells, and thus lead to CNS damage such as
demyelination. Therefore, the physiological control of auto-
reactive T cells in the CNS is likely to have an important role in
preventing the development of autoimmune CNS disorders such
as multiple sclerosis (MS) (Pender, 1998). T-cell apoptosis in
the CNS is an important mechanism for controlling autoimmune
attack on the CNS (Pender et al., 1991, 1992; Schmied et al.,
1993; Tabi et al., 1994, 1995; Gold et al., 1997; Pender and Rist,
2001). B-cell apoptosis in the CNS may also be important in
terminating autoimmune attack on the CNS (White et al., 2000).
Thus one potential therapeutic approach for treating and
preventing autoimmune CNS diseases such as MS is to
augment the apoptotic elimination of autoreactive T cells and
B cells in the CNS. This review will focus on the regulation of
neuroinflammation by lymphocyte apoptosis in the CNS.
2. Role of lymphocyte apoptosis in the CNS
T-cell apoptosis in the CNS has been studied mainly in
experimental autoimmune encephalomyelitis (EAE), a T-cell-
mediated inflammatory demyelinating disease of the CNS that is
widely studied as a model of MS. T-cell apoptosis occurs in the
CNS in acute EAE and plays an important role in the
spontaneous recovery from disease (Pender et al., 1991, 1992;
Schmied et al., 1993; Tabi et al., 1994, 1995; McCombe et al.,
1996a; Bauer et al., 1998). The main site of T-cell apoptosis is
the CNS parenchyma rather than the perivascular space or
meninges (Schmied et al., 1993; Bauer et al., 1998). The
apoptotic T cells are phagocytosed by macrophages, microglia,
astrocytes and oligodendrocytes (Nguyen and Pender, 1998;Magnus et al., 2002). It should be noted that other inflammatory
cells, such as macrophages and microglia (Nguyen et al., 1994,
1997; White et al., 1998a; Kohji and Matsumoto, 2000) and B
lymphocytes (White et al., 2000), also undergo apoptosis in the
CNS in acute EAE. To study T-cell apoptosis in the CNS, it is
therefore essential to demonstrate apoptosis of cells expressing
T-cell markers rather than simply to demonstrate apoptosis in an
unlabelled inflammatory cell infiltrate.
An important question concerns the antigen specificity of the
T cells undergoing apoptosis in the CNS, as this is relevant to
both the significance and mechanisms of T-cell apoptosis
(Pender and Rist, 2001). It is clear that encephalitogenic T cells
are rapidly eliminated from the CNS by apoptosis during
spontaneous recovery from acute EAE (Tabi et al., 1994, 1995;
McCombe et al., 1996a; Bauer et al., 1998), but there is
controversy regarding the selectivity of the process for CNS-
reactive T cells. One study found that Vβ8.2+ MBP-specific T
cells were selectively eliminated from the CNS by apoptosis in
rats recovering from EAE induced by the passive transfer of an
encephalitogenic Vβ8.2+ MBP-specific T-cell clone, whereas T
cells specific for the non-CNS antigen ovalbumin survived in
the CNS and recirculated to the peripheral lymphoid organs
(Tabi et al., 1994, 1995). This study could not exclude the
possibility that some ovalbumin-reactive T cells also underwent
apoptosis in the CNS. Using T cells carrying a specific genetic
marker, Bauer et al. (1998) demonstrated that ovalbumin-
specific T cells and MBP-specific T cells both undergo
apoptosis in the CNS in EAE. They concluded that T-cell
apoptosis occurs in a nonselective manner and is not dependent
on antigen recognition in the CNS. However, in their study the
level of ovalbumin-specific T-cell apoptosis appeared to be
considerably less than the level of MBP-specific T-cell
apoptosis, suggesting that there may be two mechanisms for
T-cell apoptosis in the CNS in EAE, one involving specific
antigen recognition and one not.
The occurrence of T-cell apoptosis in the CNS of bone-marrow
chimeric rats with EAE induced by the passive transfer of
encephalitogenic T cells expressing different major histocompat-
ibility complex (MHC) genes than the resident CNS cells has been
interpreted as indicating that T-cell apoptosis is not dependent on
antigen presentation byCNS parenchymal glial cells (Bauer et al.,
1998). However, the T-cell receptors (TCR) of the encephalito-
genic T cells may still interact with the MHC–peptide complexes
of the CNS parenchymal cells in an alloreactive response because
of the MHC mismatch, and the encephalitogenic T cells may be
deleted in the same way as Tcells are deleted by apoptosis in liver
transplants (Qian et al., 1997).
When EAE is reinduced in Lewis rats by active immuniza-
tion with MBP and complete Freund's adjuvant after recovery
from EAE induced by passively transferred MBP-specific T
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tory cells in the spinal cord compared to that occurring in the
first attack, indicating that previous CNS inflammation
increases the level of inflammatory cell apoptosis (Gordon
et al., 2001). Flügel et al. (2000) reported the remarkably rapid
apoptotic elimination of MBP-specific T cells in the CNS in the
vicinity of the axotomized facial nucleus. This indicates that
noninflammatory insults to the CNS may also accelerate T-cell
apoptosis.
T-cell apoptosis also occurs in the CNS in viral encephalo-
myelitis (Barac-Latas et al., 1994) and in human glioblastoma
multiforme (Didenko et al., 2002; Walker et al., 2006) but the
antigen specificity of the apoptotic T cells has not been
determined. If T-cell apoptosis in glioblastoma multiforme
involves tumour-specific T cells, this could contribute to the
failure of the immune system to eliminate the malignant cells.
Little attention has been given by researchers to the
potentially important role that apoptotic elimination of B cells
plays in terminating immune attack on the CNS. B-cell
apoptosis occurs in the CNS during spontaneous recovery
from acute EAE (White et al., 2000) but the antigen specifity of
the apoptotic B cells has not been determined.
3. Mechanisms of T-lymphocyte apoptosis in the CNS
The possible mechanisms of T-cell apoptosis in the CNS are
summarized in Table 1.Table 1
Possible mechanisms of T-cell apoptosis in the CNS
Mechanism Receptor activating (+) or
inhibiting (−) apoptosis
Activation-induced apoptosis (AICD) CD95 and other death recepto
such as TNFR1 (+)
Cytokine withdrawal CD28 (−)
Cytokine receptor,
e.g. IL-2R (−)
Glucocorticoids (GC) GR (+)
Ligation of T-cell CD95 by CD95L expressed by
microglia, astrocytes or neurons
CD95 (+)
Regulatory T cells
Reactive oxygen intermediates and NO
Multifunctional proteins, e.g. osteopontin
Abbreviations: AICD = activation-induced cell death; GC = glucocorticoids; GR =3.1. Activation-induced apoptosis
Activation-induced apoptosis refers to the apoptosis of
thymocytes or previously activated mature T cells, triggered by
activation through the TCR (Smith et al., 1989; Russell et al.,
1991b). The signalling pathways for activation-induced T-cell
apoptosis are illustrated in Fig. 1. Activation-induced apoptosis of
mature T cells is mediated through the activation of the Fas
(CD95) pathway and related death receptor pathways, such as the
tumour necrosis factor (TNF) receptor 1 (TNFR1) pathway
(Alderson et al., 1995; Brunner et al., 1995; Dhein et al., 1995; Ju
et al., 1995; Ashkenazi and Dixit, 1998). The CD95 pathway is
activated by ligation of cell surface CD95 by CD95 ligand
(CD95L; also known as Fas ligand) and can occur through the
interaction of CD95 andCD95Lon the sameTcell (Brunner et al.,
1995; Dhein et al., 1995). TCR ligation upregulates CD95
expression (Brunner et al., 1995; Ju et al., 1995) and induces the
expression of CD95L (Alderson et al., 1995; Brunner et al., 1995;
Ju et al., 1995). The intracellular signalling pathway for CD95 and
related death receptors is dependent on the activity of cysteine
proteases (caspases) (Ashkenazi and Dixit, 1998). Ligation of
CD95 by the homotrimeric CD95L results in the clustering of
CD95 and the recruitment of the adaptor protein Fas-associated
death domain (FADD) to the clustered CD95 intracellular death
domains. Pro-caspase-8 binds to FADD and is then cleaved to
active caspase-8 by self-cleavage as a result of induced
oligomerization. In T cells, interferon γ (IFN-γ) is required forIntracellular signaling molecules activating (+)
or inhibiting (−) apoptosis
Requirement for
antigen recognition
rs Caspase-8 (+) Yes
FLIP (−)
tBID (+)
BIM (+)
BAD (+)
BCL-2 (−)
BCL-XL (−)
BAX/BAK (+)
BIM (+) No
BAD (+)
BCL-2 (−)
BCL-XL (−)
BAX/BAK (+)
BIM (+) No. GC inhibit AICD
BCL-2 (−)
BAX/BAK (+)
Caspase-8 (+) No
FLIP (−)
tBID (+)
BIM (+)
BAD (+)
BCL-2 (−)
BCL-XL (−)
BAX/BAK (+)
glucocorticoid receptor; NO = nitric oxide.
Fig. 1. Signalling pathways for T-cell apoptosis in the CNS. Activation-induced cell death is mediated through the CD95 pathway, which activates caspase-8, which
cleaves BID to form truncated BID (tBID). If tBID is not sequestered by BCL-2/BCL-XL, it activates BAX to permeabilize the mitochondrial outer membrane so that
cytochrome c (which activates caspase-3) and other mediators of apoptosis are released from the mitochondria. CD95 can be activated by CD95 ligand (CD95L)
expressed by the same T cell. TCR ligation induces the expression of CD95L, increases the expression of CD95 and increases the expression of BIM, which if not
sequestered by BCL-2/BCL-XL, will activate BAX/BAK. Costimulation through CD28 inhibits the CD95-mediated activation of caspase-8 and also induces the
expression of IL-2, which in turn increases the expression of BCL-2//BCL-XL and induces the phosphorylation and subsequent inactivation of BAD.
Dephosphorylated BAD translocates from the cytoplasm to the mitochondria where it binds to BCL-2/BCL-XL and displaces BIM and tBID, which can then activate
BAX/BAK. Blue arrows indicate production or facilitation; red lines indicate inhibition; and black arrows indicate movement of molecules. Abbreviations: APC =
antigen-presenting cell; IL-2R=IL-2 receptor; MHC = major histocompatibility complex molecule; Ag = antigen; FADD = Fas-associated death domain.
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(Liu and Janeway, 1990; Refaeli et al., 2002).
Activated caspase-8 mediates apoptosis by cleaving the pro-
apoptotic molecule BID into a truncated form (tBID) that
promotes cytochrome c release from mitochondria, with the
resultant activation of downstream effector caspases such as
caspase-3 (Li et al., 1998; Luo et al., 1998). BID is a member of
the BCL-2 family, the members of which play a crucial role in
the regulation of apoptosis (Kim et al., 2006). The BCL-2
family contains anti-apoptotic and pro-apoptotic members and
is divided into three groups which are defined by the homology
shared within four conserved BCL-2 homology domains (BH1–
4). The classification and roles of the BCL-2 family members
are summarized in Table 2. The anti-apoptotic molecules, which
include BCL-2 and BCL-XL, display sequence conservation
through BH1–4. The pro-apoptotic members are divided into:
(i) more fully conserved multidomain members (BAX and
BAK) which have homology in the BH1–3 domains; and (ii)
members which have homology only in the BH3 domain (BH3-
only molecules). In viable cells, the multidomain pro-apoptoticmolecules exist as inactive monomers in the cytosol (BAX) or at
the mitochondria (BAK). Following activation, BAX inserts
into the mitochondrial outer membrane as homo-oligomers, and
BAK also homo-oligmerizes, resulting in the permeabilization
of this membrane and release of intermembrane space proteins,
including cytochrome c. The BH3-only pro- apoptotic members
are further subdivided into: (a) activators (e.g. tBID and BIM)
which directly activate BAX/BAK and which are prevented
from doing so by being bound to, and sequestered by, the anti-
apoptotics BCL-2/BCL-XL; and (b) ‘inactivators’ (e.g. BAD)
which do not directly activate BAX/BAK but inactivate the
anti-apoptotics by preventing their sequestration of the
activators, for example BAD displaces tBID/BIM from BCL-
2/BCL-XL to activate BAX/BAK (Kim et al., 2006).
It has previously been thought that in some T cells, the
CD95-mediated death pathway occurs independently of the
activation of BID, the translocation of BAX to the mitochondria
and the release of cytochrome c, if a large amount of caspase-
8 is activated (Scaffidi et al., 1998). However, recent studies
indicate that the activation of BID, the translocation of BAX to
Table 2
Members of BCL-2 family and roles in apoptosis
Group
Anti-apoptotic Pro-apoptotic
Multidomain Activator BH3-only Inactivator BH3-only
Domains of BCL-2
homology (BH)
BH1 BH1 BH3 BH3
BH2 BH2
BH3 BH3
BH4
Members BCL-2 BAX BID BAD
BCL-XL BAK BIM BIK
BCL-W PUMA HRK
MCL-1 NOXA
BMF
Function Sequestering the activators
(BID, BIM and PUMA)
Permeabilization of mitochondrial outer
membrane with release of cytochrome c
Direct activation of
BAX and BAK
Inactivation of the anti-apoptotics by
preventing their sequestration of the activators
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CD95-triggered apoptosis in all cell types (Tafani et al., 2006).
TCR ligation also upregulates the expression of the activator
BIM (Sandalova et al., 2004), in addition to upregulating CD95
expression and inducing CD95L expression. Thus, in vivo, BIM
and tBID may act synergistically to induce apoptosis following
TCR ligation.
Several studies have attempted to examine the role of the
CD95 pathway and TNFR1 pathway in T-cell apoptosis in the
CNS by using mice which are genetically deficient in the
expression of CD95, CD95L or TNFR1 (reviewed by Pender
and Rist, 2001). However, because deficiency of these
molecules generally inhibits the induction and/or effector
phase of EAE, the effect on T-cell apoptosis is difficult to
interpret, with the exception of SJL mice where the CD95
pathway does not play a major role in the induction/effector
phase. In CD95-deficient SJL mice, the severity of EAE is
increased in association with decreased apoptosis of inflamma-
tory cells in the CNS, indicating that the CD95 pathway is
involved in lymphocyte apoptosis in the CNS (Suvannavejh
et al., 2000). An alternative experimental approach analyzing the
expression of CD95 and CD95L by T cells in the CNS has
indicated that the CD95 pathway is involved in T-cell apoptosis
in the CNS during recovery from EAE in the rat (White et al.,
1998b). T cells, particularly Vβ8.2+ T cells (representing the
encephalitogenic MBP-specific T cells), express CD95 and
CD95L in the CNS of rats with acute EAE (White et al., 1998b;
Kohji and Matsumoto, 2000). During spontaneous recovery
from acute EAE induced by immunization with MBP, Vβ8.2+ T
cells expressing CD95 or CD95L are much more vulnerable to
apoptosis in the CNS than Vβ8.2+ T cells not expressing these
proteins (White et al., 1998b). The susceptibility of Vβ8.2+ T
cells expressing these molecules is further increased by the
intraperitoneal administration of soluble MBP which reduces
the severity of EAE (Ishigami et al., 1998). The vulnerability of
CD95L-expressing T cells to apoptosis suggests that ligation
of CD95 by CD95L on the same T cell contributes to T-cell
apoptosis in the CNS. Administration of anti-CD95L antibody to
Lewis rats after the clinical peak of EAE decreases the apoptosis
of inflammatory cells in the CNS, increases the severity ofinflammation in the CNS and delays clinical recovery (Wild-
baum et al., 2000). The importance of death receptor-mediated
lymphocyte apoptosis in the CNS for recovery from EAE has
also been demonstrated by the finding that overexpression of
FLIP, which inhibits apoptosis mediated through CD95 and
related death receptors by preventing the activation of pro-
caspase-8, decreases the clearance of Tcells and B cells from the
CNS and exacerbates EAE in DBA/1 mice (Djerbi et al., 2003).
In human glioblastoma multiforme, T cells expressing
CD95L are eight times more vulnerable to apoptosis than
those not expressing CD95L, suggesting that T-cell apoptosis is
induced by overactivation of the TCR (Walker et al., 2006).
3.2. T-cell apoptosis due to impairment of costimulation and
withdrawal of growth factor
Impairment of costimulation and withdrawal of growth factor
are two related mechanisms that contribute to T-cell apoptosis in
the CNS. The signalling pathways whereby costimulation
modulates T-cell apoptosis are illustrated in Fig. 1. Costimula-
tion of previously activated T cells influences their survival by
two mechanisms: (i) inhibiting CD95-mediated activation-
induced cell death; and (ii) increasing the production of growth
factors (particularly interleukin-2 [IL-2]), withdrawal of which
can induce T-cell apoptosis through a CD95-independent
mechanism. Compared with peripheral lymphoid organs, the
normal CNS has few professional antigen-presenting cells
(APC) but many non-professional APC such as microglia and
astrocytes, which can express MHC molecules and present
antigen to T cells but which do not provide costimulatory
signals. It has been suggested that CNS-reactive T cells are
vulnerable to activation-induced apoptosis in the CNS because
of a lack of costimulatory survival signals in the CNS (Pender
et al., 1992; Tabi et al., 1994; Pender, 1999). This could explain
why soluble antigen therapy induces apoptosis of autoreactive T
cells preferentially in the CNS rather than in the peripheral
lymphoid organs (Ishigami et al., 1998).
Costimulation by professional APC (Liu and Janeway, 1990;
Groux et al., 1993) or by the direct ligation of the T-cell
costimulatory receptor CD28 (Collette et al., 1997) inhibits
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Costimulation through CD28 can inhibit CD95-mediated T-cell
apoptosis by several mechanisms: (i) preventing the induction of
CD95L expression in T cells (Collette et al., 1997); (ii) inhibiting
the CD95-mediated activation of caspase-8 (Jones et al., 2002);
and (iii) increasing the expression of IL-2 which (a) upregulates
the expression of the anti- apoptotic molecules, BCL-2 and BCL-
XL, and (b) inactivates the pro-apoptotic molecule BAD by
phosphorylation. Costimulation of previously activated T cells
increases their expression of IL-2 (Schweitzer and Sharpe, 1998),
which inhibits activation-induced T-cell apoptosis (Groux et al.,
1993; Ford et al., 1996). IL-2 increases the expression of BCL-2
(Deng and Podack, 1993; Akbar et al., 1996; Mor and Cohen,
1996; Mueller et al., 1996) and BCL-XL (Akbar et al., 1996;
Mueller et al., 1996). The inhibitory effect of BCL-2 and BCL-XL
on activation-induced T-cell death can be accounted for by their
sequestration of tBID and subsequent inhibition of the CD95-
mediated death pathway, as discussed above in Section 3.1,
summarized in Table 2 and illustrated in Fig. 1. IL-2 also induces
the phosphorylation of BAD so that it is retained in the cytoplasm
and does not translocate to the mitochondria (Ayllón et al., 2000),
where it can displace tBID from BCL-2/BCL-XL to activate
BAX/BAK (Kim et al., 2006) (Table 2). This displacement of
tBID by BAD can account for the ability of BAD to augment
CD95-triggered apoptosis in thymocytes (Mok et al., 1999).
Growth factor withdrawal can also trigger apoptosis through
a pathway not dependent on CD95 or related death receptors
(Strasser, 2005). It has been shown that, following the
withdrawal of superantigen from superantigen-activated T
cells, the Tcells undergo apoptosis through a CD95-independent
pathway that is mediated by the pro-apoptotic molecule BIM and
inhibited by BCL-2, the level of which decreases just before the
occurrence of T-cell apoptosis (Hildeman et al., 2002). It was
suggested that the reduction in BCL-2 expression was at least
partly due to cytokine withdrawal because cytokines including
IL-2, IL-4, IL-7 and IL-15 that signal through the common γ
chain of the IL-2 receptor can induce BCL-2 expression, as well
as BCL-XL expression (Akbar et al., 1996). Withdrawal of IL-2,
IL-4 or IL-7 from T cells results in the dephosphorylation of
BAD (Ayllón et al., 2000; Fleischer et al., 2004; Li et al., 2004),
which then translocates from the cytoplasm, where it is bound in
its phosphorylated form to 14-3-3 proteins, to the mitochondria
where it can displace BIM and tBID from BCL-2/BCL-XL to
activate BAX/BAK (Kim et al., 2006) (Table 2). As mentioned
in Section 3.1, TCR ligation also upregulates the expression of
BIM (Sandalova et al., 2004), so that whether a T cell undergoes
apoptosis or not upon cytokine withdrawal will be influenced by
its recent history of TCR ligation.
Several studies have examined the effects of BCL-2/BCL-XL
expression or CD28 costimulation on T-cell apoptosis in the
CNS in EAE. In Lewis rats with EAE, Vβ8.2+ Tcells expressing
BCL-2 are less vulnerable to apoptosis in the CNS than Vβ8.2+
cells not expressing BCL-2 (White et al., 1998b). In mice, the
transgenic overexpression of BCL-XL in T cells decreases the
apoptosis of inflammatory cells in the CNS and increases the
severity of EAE (Issazadeh et al., 2000). Similarly, transgenic
overexpression of BCL-2 in T cells decreases the apoptosis of Tcells in the CNS and increases the severity of EAE (Okuda et al.,
2002). In contrast, the transfer of encephalitogenic T cells to
mice deficient in the costimulatory molecules CD80 and CD86
resulted in increased apoptosis of inflammatory cells in the CNS
and decreased the severity of EAE (Chang et al., 2003). Taken
together, these studies in EAE indicate that the levels of T-cell
costimulation and T-cell expression of BCL-2 and BCL-XL in
the CNS are important modulators of T-cell apoptosis in the
CNS. However, they do not reveal whether this modulation is
occurring by modifying CD95-mediated activation-induced T-
cell death or by modifying the CD95-independent apoptotic
response to growth factor, for example IL-2, withdrawal. The
first of these processes would involve only T cells recognizing
their antigen within the CNS, whereas the second could effect
any T cell in the CNS. It is possible that some CNS-reactive T
cells are deleted by the first process and some by the second. It is
also possible that the fate of each individual CNS-reactive T cell
is influenced by synergy between both apoptotic pathways.
Thus, whether TCR reactivation in the CNS results in T-cell
death or survival depends on the balance between pro-apoptotic
and anti-apoptotic factors affecting each T cell.
3.3. Glucocorticoid-induced apoptosis
Another possible mechanism for T-cell apoptosis in the CNS is
glucocorticoid-induced apoptosis. Glucocorticoids exert their
many effects on the immune system by binding to the
glucocorticoid receptor (GR), a ligand-dependent transcription
factor. Although it has long been known that glucocorticoids can
induce T-cell apoptosis (Nieto and López-Rivas, 1989), the
mechanism for this remains unclear. Glucocorticoids inhibit the
production of IL-2 (Boumpas et al., 1991), which can induce the
expression of BCL-2 and BCL-XL and protect T cells from
glucocorticoid-induced apoptosis (Nieto and López-Rivas, 1989;
Mor and Cohen, 1996). At least in T-cell acute lymphoblastic
leukemic cells, glucocorticoid-induced apoptosis depends on the
induction of the pro-apoptotic molecule BIM (Lu et al., 2006),
which directly activates BAX/BAK unless sequestered by BCL-
2/BCL-XL.
Glucocorticoids are endogenously released during spontane-
ous recovery from acute EAE (MacPhee et al., 1989).
Adrenalectomy, which prevents the production of glucocorti-
coids, reduces the level of T-cell apoptosis in the CNS in EAE,
suggesting that glucocorticoids may contribute to the T-cell
apoptosis (Smith et al., 1996). However, glucocorticoid release
is not solely responsible for the T-cell apoptosis because T-cell
apoptosis occurs in the CNS during recovery from mild EAE
without glucocorticoid release (Smith et al., 1996). It should also
be noted that adrenalectomy not only prevents the increased
glucocorticoid production that occurs in EAE but also abrogates
basal glucocorticoid production, which itself could modulate the
levels of cytokines and pro-apoptotic and anti-apoptotic mol-
ecules in the CNS and thereby influence activation-induced T-
cell apoptosis and cytokine-withdrawal apoptosis. Therefore, it
not known whether the increased endogenous release of gluco-
corticoids in EAE is sufficient to increase T-cell apoptosis above
that which might occur with basal glucocorticoid secretion.
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the selective apoptotic elimination of CNS-reactive Tcells in the
CNS in EAE (Tabi et al., 1994, 1995) because the administration
of exogenous glucocorticoids actually inhibits the selective
apoptosis of Vβ8.2+ cells representing MBP-specific T cells in
the CNS (McCombe et al., 1996b). This inhibition can be
accounted for by the ability of glucocorticoids to antagonize
activation-induced cell death (Zacharchuk et al., 1990), by
reducing the expression of CD95L (Yang et al., 1995; Baumann
et al., 2005), and possibly by also directly inhibiting the CD95
pathway (Zipp et al., 2000).
3.4. T-cell apoptosis induced by ligation of T-cell CD95 by
CD95L expressed by astrocytes, microglia or neurons
In addition to activation-induced T-cell apoptosis, where
activation of the TCR drives the T cell through the CD95-
mediated death pathway, there is another possible pathway for
CD95-mediated T-cell death in the CNS, where CD95L
expressed by astrocytes, microglia or neurons might interact
with T-cell CD95 in an antigen-independent manner. In Lewis
rats with EAE, apoptotic inflammatory cells associate with
astrocytes (Kohji et al., 1998), and astrocytes express CD95L,
leading to the suggestion that CD95L-expressing astrocytes
induce T-cell apoptosis in the CNS by ligating T-cell CD95
(Kohji and Matsumoto, 2000). Astrocytes expressing CD95L
can induce apoptosis in target cells in vitro (Bechmann et al.,
1999; Choi et al., 1999). Similarly, microglia can express
CD95L and can induce apoptosis in CD95-expressing target
cells in vitro (Frigerio et al., 2000). However, it remains unclear
whether, in vivo, CD95L expressed by astrocytes and microglia
plays a role in inducing T-cell apoptosis. Because such a
mechanism does not depend on antigen recognition by T cells, it
could affect any T cell in the CNS. An alternative role for
astrocytes and microglia in inducing T-cell apoptosis is that
astrocytes and microglia present CNS antigens to T cells but fail
to provide costimulation, and thereby lead to activation-induced
T-cell apoptosis through the interaction of CD95L and CD95 on
the same T cell (Pender, 1999). This is consistent with the
finding that antigen presentation to MBP-specific T cells by
microglia in vitro results in T-cell apoptosis, which can be
prevented by the addition of IL-2 (Ford et al., 1996). The fact
that microglia express considerably higher levels of class II
MHC molecules than astrocytes in rats with EAE and that this
increases during the disease course (Matsumoto et al., 1986)
indicates that microglia are more likely than astrocytes to
present antigens to CD4+ T cells in vivo. The association of
apoptotic inflammatory cells with astrocytes in the CNS (Kohji
et al., 1998) might be the effect rather than the cause of
apoptosis, as astrocytes can phagocytose apoptotic lymphocytes
in EAE (Nguyen and Pender, 1998).
Neurons can also express CD95L (Bechmann et al., 1999;
Flügel et al., 2000) and can induce apoptosis of MBP-specific T
cells in vitro (Flügel et al., 2000). Because MBP-specific T cells
rapidly undergo apoptosis in the immediate vicinity of CD95L-
expressing neurons of the axotomized facial nerve in vivo, it has
been concluded that the T-cell apoptosis is due to the directligation of T-cell CD95 by neuronal CD95L (Flügel et al.,
2000). However, microglia express class II MHC molecules
following axotomy (Streit et al., 1989), and it is possible that the
apoptotic elimination of MBP-specific T cells after axotomy is
dependent on antigen presentation by microglia and represents
activation-induced cell death through interaction of CD95 and
CD95L on the same T cell. The close association of apoptotic T
cells with, and their internalization by, neurons (Flügel et al.,
2000) may be the result rather than the cause of apoptosis, if
neurons can phagocytose apoptotic lymphocytes in the same
way as oligodendrocytes and astrocytes can (Nguyen and
Pender, 1998).
3.5. Other possible mechanisms of T-cell apoptosis in the CNS
It has been suggested that reactive oxygen intermediates and
nitric oxide released by macrophages in the CNS may be
responsible for T-cell apoptosis in the CNS in EAE (Zettl et al.,
1997). However, Bachmann et al. (1999) found that the level of
T-cell apoptosis in the CNS in mice with EAE was not altered
by deficiency of inducible nitric oxide synthase and concluded
that nitric oxide does not have a major role in inducing T-cell
apoptosis in the CNS.
Another possible mechanism for T-cell apoptosis in the CNS
is that induced by regulatory T cells. T cells specifically targeted
against encephalitogenic T cells can kill the latter cells in vitro
(Sun et al., 1988). γδ T cells expressing CD95L can induce
apoptosis in encephalitogenic T cells in vitro, and mice deficient
in γδ T cells have decreased apoptosis of encephalitogenic T
cells in the CNS and fail to recover from EAE (Ponomarev and
Dittel, 2005).
Given the complexity of apoptotic signalling pathways, it is
likely that many, as yet unstudied, endogenous proteins are able
to modulate T-cell apoptosis in the CNS. Recently it has been
shown that the multifunctional protein, osteopontin, inhibits the
apoptosis of activated T cells in vitro, promotes survival of
inflammatory cells in the CNS and worsens the disease course
in mice with EAE (Hur et al., 2007).
4. Mechanisms of B-lymphocyte apoptosis in the CNS
The possible mechanisms of B-cell apoptosis in the CNS are
summarized in Table 3. Apoptosis can be induced in mature B
cells by hyper-crosslinking the B-cell antigen receptor (BCR)
(Hartley et al., 1991; Russell et al., 1991a); this does not involve
the interaction of CD95 and CD95L (Peter et al., 1995; Lens
et al., 1996). The degree of cross-linking of surface immuno-
globulin (sIg) receptors on mature B cells determines whether
the B cells proliferate or are deleted; weak sIg cross-linking
induces B cells to proliferate, whereas strong sIg cross-linking
by multivalent antigens such as cell membrane antigens
eliminates B cells by apoptosis (Parry et al., 1994; Tsubata
et al., 1994). BCR ligation increases the expression of BIM
(Craxton et al., 2005), which, if not sequestered by BCL-2/
BCL-XL, induces apoptosis by directly activating BAX/BAK.
B-cell activating factor (BAFF) blocks BCR-induced apoptosis
by downregulating the expression of BIM and by inducing the
Table 3
Possible mechanisms of B-cell apoptosis in the CNS
Mechanism Receptor activating (+) or inhibiting
(−) apoptosis
Intracellular signaling molecules activating (+) or
inhibiting (−) apoptosis
Requirement for antigen
recognition by B cell
Hyper-cross-linking of
BCR
BCR (+) BIM (+) Yes
BAFF-R (−) BAD (+)
IL-4R (−) BCL-XL (−)
CD40 (−) BCL-2 (−)
BAX/BAK (+)
Ligation of B-cell CD95 by
CD95L expressed by:
(i) T cells
(ii) same B cell
(iii) microglia, astrocytes
or neurons
CD95 (+)
BCR (−)
IL-4R (−)
Caspase-8 (+)
FLIP (−)
tBID (+)
BAD (+)
BCL-XL (−)
BCL-2 (−)
BAX/BAK (+)
No
Cytokine withdrawal IL-4R (−) BIM (+) No
BAD (+)
BCL-XL (−)
BCL-2 (−)
BAX/BAK (+)
Glucocorticoids GR (+) BIM (+) No
BCL-2 (−)
BAX/BAK (+)
Abbreviations: BAFF = B-cell activating factor; BAFF-R = BAFF receptors (BR3, BCMA and TACI); GR = glucocorticoid receptor.
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subsequent degradation by the proteasome (Craxton et al.,
2005). At least in immature B cells, BCR ligation results in the
dephosphorylation of BAD (Malissein et al., 2003), which then
translocates from the cytoplasm to the mitochondria where it
can displace BIM from BCL-2/BCL-XL to activate BAX/BAK.
BCR-triggered apoptosis is dependent on the absence of T-cell
signals, because it can be inhibited by IL-4 (Parry et al., 1994)
and ligation of CD40, which is constitutively expressed on B
lymphocytes (Valentine and Licciardi, 1992; Tsubata et al.,
1993; Lens et al., 1996). The anti-apoptotic effect of IL-4 is
explained by its ability to increase the expression of BCL-XL
(Wurster et al., 2002) and, at least in chronic lymphocytic
leukemic B cells, BCL-2 (Dancescu et al., 1992). It is also likely
that IL-4 inhibits B-cell apoptosis by promoting the phosphor-
ylation and subsequent inactivation of BAD, as it does in T cells
(Fleischer et al., 2004), as discussed above in Section 3.2. The
anti-apoptotic action of CD40 ligation is due to its ability to
upregulate the expression of BCL-XL (Craxton et al., 2005).
Another mechanism of apoptosis in mature B cells is
mediated through CD95, the expression of which is upregulated
by the ligation of B-cell CD40 by activated T cells expressing
CD40L (Garrone et al., 1995; Rothstein et al., 1995). This
CD40L-triggered CD95-mediated apoptosis can be overcome
by BCR ligation (Rothstein et al., 1995) which inhibits the
CD95-mediated activation of caspase-8 (Hinshaw et al., 2003),
although antigen-specific B cells that have been activated for a
prolonged period can become sensitive to CD95-mediated cell
death (Wang et al., 1996). CD40 signalling can also inhibit the
CD95-induced activation of caspase-8 (Benson et al., 2006). IL-
4 also inhibits CD95-mediated apoptosis in B cells (Foote et al.,
1996; Wurster et al., 2002), which can be explained by its ability
to increase the expression of BCL-XL (Wurster et al., 2002) and
BCL-2 (Dancescu et al., 1992) and to inactivate BAD (Fleischeret al., 2004). The CD95-mediated pathway is postulated to
result from the ligation of B-cell CD95 by T-cell CD95L
(Rathmell et al., 1996). However, activated B cells express
functional CD95L (Hahne et al., 1996) as well as CD95 (Wang
et al., 1996), which raises the possibility that the interaction of
CD95L and CD95 on the same B cell may mediate apoptosis.
Cytokine withdrawal is another mechanism of B-cell
apoptosis. IL-4 can rescue B cells from spontaneous apoptosis
in vitro (Illera et al., 1993) by increasing the expression of BCL-
2/BCL-XL and by inactivating BAD, as discussed above. In the
IL-3-dependent B-cell line Ba/F3, IL-3 induces phosphorylation
of BIM, which promotes its ubiquitination and subsequent
degradation by the proteasome (Qi et al., 2006) so that it can no
longer activate BAX/BAK.
Apoptosis can also be induced in mature B cells by gluco-
corticoids (Andréau et al., 1998), which, at least in chronic
lymphocytic leukemic B cells, upregulate the expression of BIM
(Iglesias-Serret et al., 2007), as they do in T-cell acute
lymphoblastic leukemic cells (Lu et al., 2006). Another possible
mechanism of B-cell apoptosis in the CNS is ligation of B-cell
CD95 by CD95L expressed by microglia, astrocytes or neurons,
as suggested for T-cell apoptosis in Section 3.4.
During spontaneous recovery from acute EAE, B cells
expressing CD95 and B cells expressing CD95L are highly
vulnerable to apoptosis in the CNS, whereas B cells expressing
BCL-2 are protected from apoptosis (White et al., 2000). The
vunerability of B cells expressing CD95L to apoptosis in the CNS
suggests that B-cell apoptosis is mediated by the interaction of
CD95L and CD95 on the same B cell. White et al. (2000)
hypothesized that CD95-mediated apoptosis occurs in CNS B
cells that are expressing low levels of BCL-2 because of cytokine
withdrawal following activation-induced apoptosis of encepha-
litogenic Tcells. A role for CD95 in mediating B-cell apoptosis in
the CNS is also suggested by the finding that overexpression of
34 M.P. Pender / Journal of Neuroimmunology 191 (2007) 26–38FLIP, which inhibits CD95-mediated apoptosis, reduces the
clearance of B cells from the CNS in EAE (Djerbi et al., 2003). It
is also possible that some B cells are being deleted in the CNS by
non-CD95-dependent mechanisms, such as BCR hyper-cross-
linking or by the action of endogenous glucocorticoids, which are
released during spontaneous recovery from acute EAE (MacPhee
et al., 1989). Further studies are warranted to investigate the role
and mechanisms of B-cell apoptosis in the CNS.
5. Strategies for promoting lymphocyte apoptosis in the
CNS
5.1. Glucocorticoid-induced lymphocyte apoptosis
Glucocorticoids exert a variety of immunomodulatory
activities on inflammation in the CNS (Reichardt et al., 2006),
and high-dose intravenous glucocorticoid therapy is widely
used to treat relapses of MS. The administration of exogenous
glucocorticoids increases the level of T-cell apoptosis in the
CNS in EAE (McCombe et al., 1996b; Nguyen et al., 1997;
Schmidt et al., 2000, 2003). However, the beneficial effect of
glucocorticoid therapy in EAE does not depend on the induction
of increased T-cell apoptosis in the CNS because EAE can be
inhibited by low doses of dexamethasone which do not increase
T-cell apoptosis in the CNS (Nguyen et al., 1997). It should also
be noted that, although higher glucocorticoid doses increase the
overall level of T-cell apoptosis in the CNS (McCombe et al.,
1996b; Nguyen et al., 1997), they actually inhibit the selective
apoptosis of encephalitogenic T cells in the CNS in EAE
(McCombe et al., 1996b). This may contribute to the relapses of
EAE that occur after cessation of glucocorticoid therapy
(Nguyen et al., 1997). It is likely that glucocorticoid therapy
also increases the level of B-cell apoptosis in the CNS but this
has not yet been investigated.
5.2. Soluble antigen administration
The parenteral administration of high doses of soluble myelin
antigen increases T-cell apoptosis in the CNS and reduces the
severity of EAE (Ishigami et al., 1998; Weishaupt et al., 2000;
Tischner et al., 2007). It is possible that soluble antigen therapy
also increases B-cell apoptosis in the CNS but this has not yet
been studied.
5.3. Intrathecal IFN-γ administration
The intrathecal delivery of IFN-γ by an IFN-γ-gene-
containing vector increases the apoptosis of lymphocytes in
the CNS and reduces the severity of EAE (Furlan et al., 2001).
Because this therapy increases the expression of TNFR1 by
inflammatory cells in the CNS, it has been suggested that the
augmentation of apoptosis is mediated through TNFR1 (Furlan
et al., 2001). However, because the therapy also increases the
expression of class II MHC molecules in the CNS, increased T-
cell apoptosis may occur through CD95-mediated activation-
induced apoptosis resulting from increased antigen presentation
to CD4+ T cells, in the absence of costimulatory signals.5.4. Intrathecal CD95L administration
The intrathecal infusion of recombinant CD95L greatly in-
creases the apoptosis of inflammatory cells in the CNS and reduces
the severity of EAE in Lewis rats (Zhu et al., 2002). Although
CD95 expression was observed on neurons, astrocytes and
oligodendrocytes in the CNS there was no detectable damage to
these cells or to the myelin structure after the infusion of CD95L.
5.5. Transplantation of neural precursor cells
When adult neural precursor cells are injected intravenously
into mice with EAE, the transplanted cells lodge in the
perivascular areas of the CNS where they lead to increased
apoptosis of T cells within the CNS and decreased severity of
EAE (Pluchino et al., 2005). The mechanism for the increased
T-cell apoptosis is unclear but a possible explanation is
increased activation-induced cell death driven by CNS antigens
presented by the transplanted cells or by the increased number
of microglia, in the absence of costimulatory signals.
5.6. Administration of 1,25-dihydroxyvitamin D3
The administration of 1,25-dihydroxyvitamin D3 increases
the level of apoptosis of inflammatory cells in the CNS and
decreases the severity of EAE (Spach et al., 2004). The
mechanism for the increased apoptosis of inflammatory cells is
unclear but may involve the pro-apoptotic proteins, calpain-2
and caspase-8-associated protein 2, the CNS expression of
which is increased by the administration of 1,25-dihydroxyvi-
tamin D3. On the other hand, 1,25-dihydroxyvitamin D3 can
inhibit activation-induced T-cell apoptosis by reducing the
expression of CD95L (Cippitelli et al., 2002).
5.7. Induction of B-cell apoptosis by anti-CD20 monoclonal
antibody
Monoclonal antibodies against CD20, which is expressed by
B cells, induce B-cell death by several mechanisms (Cragg and
Glennie, 2004). Rituximab and 1F5, which redistribute CD20
into membrane rafts, are bound efficiently by complement C1q,
deposit C3b, and result in complement-dependent cytotoxicity,
which is important for their in vivo efficacy. They also induce
B-cell apoptosis but to a lesser degree than the B1 anti-CD20
monoclonal antibody, which does not redistribute CD20 into
membrane rafts, bind C1q, or cause efficient complement-de-
pendent cytotoxicity. Rituximab reduces the numbers of B cells
and T cells in the cerebrospinal fluid of patients with MS (Cross
et al., 2006), but its therapeutic efficacy has not yet been
determined.
5.8. Targeting anti-apoptotic BCL-2 family members
It has previously been suggested that targeting of antisense
BCL-2 oligonucleotides to T cells in the CNS might increase T-
cell apoptosis there and be beneficial in MS (Pender, 1998), but
a major limitation of this approach is the problem of drug
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provided by ABT-737, a recently developed potent small-
molecule inhibitor of the anti-apoptotic proteins BCL-2, BCL-
XL and BCL-W (Oltersdorf et al., 2005). This compound
induces lymphopenia in vivo (Oltersdorf et al., 2005), although
normal lymphocytes are much less sensitive than chronic
lymphocytic leukemic cells (Del Gaizo Moore et al., 2007). In
chronic lymphocytic leukemic cells, ABT-737 displaces BIM
from the BH3-binding pocket of BCL-2 so that the displaced
BIM can activate BAX and induce apoptosis (Del Gaizo Moore
et al., 2007). ABT-737 has the potential to increase apoptosis of
B cells and T cells in inflammatory CNS lesions, although it is
unknown whether it can cross the blood–brain barrier.
5.9. Targeting the Epstein–Barr virus in MS
A potential approach to augmenting lymphocyte apoptosis in
the CNS in MS is to target the Epstein–Barr virus (EBV), which
has been strongly implicated in the pathogenesis of MS and
other human chronic autoimmune diseases such as systemic
lupus erythematosus (Pender, 2003). It has been hypothesized
that patients with MS have a genetic susceptibility to the effects
of B-lymphocyte infection with EBV, resulting in EBV-infected
autoreactive B cells, which could not only produce pathogenic
autoantibodies but also provide costimulatory survival signals
in the CNS to CNS-reactive T cells, that would otherwise be
deleted there by activation-induced apoptosis (Pender, 2003).
Therefore, therapies that induce apoptosis in EBV-infected B
cells in the CNS might disinhibit activation-induced T-cell
apoptosis in the CNS in MS by reducing the costimulatory anti-
apoptotic signals available to the T cells. Therapeutic
approaches to eliminating EBV-infected B cells include:
rituximab, which deletes EBV-infected B cells as well as
other CD20-expressing B cells; the transfer of autologous EBV-
specific cytotoxic T cells (Savoldo et al., 2006); and targeting
small interfering RNA to the EBV-encoded latent membrane
protein 1 (Mei et al., 2006), which plays a key role in EBV
infection of B cells by mimicking an activated CD40 receptor.
6. Conclusion
The elimination of autoreactive T cells and B cells from the
CNS by apoptosis plays an important role in switching off
autoimmune attack. Augmenting lymphocyte apoptosis in the
CNS is a potential strategy for treating autoimmune CNS
diseases such as MS. These strategies involve enhancing the
physiological pro-apoptotic pathways and blocking the phys-
iological anti-apoptotic pathways that normally control the fate
of lymphocytes in the CNS.
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